A point mutation, lysine 97 to isoleucine, in the all-beta cytokine interle
ukin-1 beta (IL-1 beta) exhibits an increased propensity to form inclusion
bodies in vivo and aggregates in vitro. In an effort to better understand t
he aggregation reaction and determine when intervention may allow rescue of
protein from aggregation during renaturation, we developed a novel applica
tion of mass spectrometry using isotopic labeling to determine the step(s)
at which K97I commits to either the native or aggregated state. Interesting
ly, despite the early formation of a folding intermediate ensemble at an ob
served rate lambda (2) of 4.0 s(-1), K97I commits to folding at a significa
ntly slower rate lambda (CF) of 0.021 s(-1). This rate of commitment to fol
ding is in excellent agreement with the observed rate of K97I native state
formation (lambda (1) = 0.018 s(-1)). K97I also commits slowly to aggregati
on at an observed rate lambda (CA) of 0.023 s(-1). Earlier folding species
and aggregates present prior to these commitment steps are likely to be in
a reversible equilibrium between monomeric folding intermediates and higher
-order oligomers. Kinetic and equilibrium experimental measurements of fold
ing and aggregation processes are consistent with a nucleation-dependent mo
del of aggregation.